Cetuximab-Induced Acneiform Eruption: A Case Report
Turkish Journal of Internal Medicine · 2022
DOI: 10.46310/tjim.1071185 ↗Kurz gefasst
Fallbericht in der Zeitschrift Turkish Journal of Internal Medicine, 2022. Verfasst von Büşra GÜNER und 2 weiteren Autor:innen. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Epidermal growth factor receptor (EGFR) monoclonal antibody inhibitors are used to treat metastatic colorectal cancers. Cetuximab, an EGFR inhibitor drug, targets specific molecular pathways and does not cause the severe systemic side effects seen in cytotoxic chemotherapy. Herein, we presented a case who developed acneiform eruptions during cetuximab treatment.
Zitieren
APA
GÜNER, B., EVRENSEL, T., & ORHAN, S. O. (2022). Cetuximab-Induced Acneiform Eruption: A Case Report. Turkish Journal of Internal Medicine. https://doi.org/10.46310/tjim.1071185
Vancouver
GÜNER B, EVRENSEL T, ORHAN SO. Cetuximab-Induced Acneiform Eruption: A Case Report. Turkish Journal of Internal Medicine. 2022. doi:10.46310/tjim.1071185
BibTeX
@article{GNER2022,
author = {GÜNER, Büşra and EVRENSEL, Türkkan and ORHAN, Sibel OYUCU},
title = {Cetuximab-Induced Acneiform Eruption: A Case Report},
journal = {Turkish Journal of Internal Medicine},
year = {2022},
doi = {10.46310/tjim.1071185}
}
EUVIMED